Case Studies

Accelerating drug discovery at the Melbourne Biomedical Precinct

33% of Australia’s 2017-2018 drug discovery efforts occurred within the Melbourne Biomedical Precinct (the Precinct) and continues to grow. The Precinct consistently attracts 23% of National Health and Medical Research Council (NHMRC) funding annually, more than any other state in Australia, and has a publication citation rate twice the international average. So why was the […]

Unique insights to inform strategic portfolio strategy

Learn how Neuland Laboratories, an India- based API manufacturer leveraged a combination of Cortellis Generics Intelligence and Cortellis Competitive Intelligence for trusted information around target products, molecules and companies, API manufacturing landscape, patent landscape, drug level sales forecast and SWOT analysis to strategically plan and manage their portfolio.

Identifying and evaluating new products to rise above the competition

Learn how the Business Development and Licensing team help Par Pharmaceutical rise above the competition by quickly and accurately identifying a shortlist of potential portfolio candidates, recognizing potential barriers to market entry, and monitoring the launch, API development and patenting activities of competitors worldwide.

Making data driven decisions with reliable intelligence

Johnson & Johnson experienced difficulties keeping up to date on the global drug pipeline and spent considerable time and expense gathering and analyzing data from multiple sources. Discover how Cortellis Competitive Intelligence helped the company apply reliable data to confidently make strategic decisions.

Securing the best price for an out-licensed asset

Biotech Ensysce seeks out-licensing or partnering opportunities around the world for its proprietary abuse and overdose resistant prodrug technologies. Learn how the company has made successful deals faster, without sacrificing due diligence, and negotiated a higher price than what it originally thought it could obtain.

Conducting pathway analyses to accelerate discovery research

Discover how researchers at Harvard University freed up the bioinformatics team by empowering biologists to analyze their own data, and made critical go/no-go decisions regarding which drugs to push through the development lifecycle by obtaining an understanding of omics data in the context of their therapeutic area

Drug repurposing for rare disease treatment leads to reduced risk

Director of the Drug Discovery Platform of Parc Científic Barcelona, Jordi Quintana and his team secured funding to investigate a rare disease, amyloidosis. They set out to study a subset of the disease called familial amyloid polyneuropathy. Because of the rare nature of the disease and the limited patient base, traditional drug discovery and development […]